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Abstract 
  
Despite decades of research on necrotizing enterocolitis, we still do not fully understand the 
pathogenesis of the disease, how to prevent or how to treat the disease. However, as a result of 
recent significant advances in the microbiology, molecular biology, and cell biology of the 
intestine of premature infants and infants with necrotizing enterocolitis, there is some hope that 
research into this devastating disease will yield some important translation into improved 
outcomes. 
 
Introduction  
Although necrotizing enterocolitis (NEC) is one of the most common life-threatening surgical 
diseases affecting neonates, we still do not completely understand the pathogenesis or how to 
prevent or treat the disease [1]. The high mortality (around 30% for surgical NEC [2, 3] and long-
term morbidity [4] [5] of survivors mandates urgent research into the pathogenesis, diagnosis, 
prevention and treatment of this devastating disease. There are several animal models of NEC, 
however, it is not completely clear how accurately these models recapitulate the human 
disease. This is particularly difficult as clinical NEC itself is quite variable, with some authors 
arguing for sub-classification into different forms reflecting the differences in disease onset and 
progression between a ‘typical’ NEC presentation in an extremely premature infant who has 
been fed enterally for a few weeks, and other presentations such as NEC in a term infant who 
has a cardiac defect or who has had gastroschisis [6]. As a consequence of the limitations of the 
animal models, it is vital to undertake clinical research studies in parallel with basic science / 
animal model studies, and in this brief review article, our aim is to describe some areas of 
current research interest; an exhaustive review of all current NEC research is unfeasible. 
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Pathogenesis 
The main factors thought to be involved in the pathogenesis of NEC are: intestinal immaturity, 
enteral feeds, the intestinal microbiome, inflammation and local ischaemia and/or reperfusion 
injury. We will briefly discuss recent research in each of these areas below. 
Intestinal immaturity 
The fetal gut develops in an environment where exposure to microbes is limited. Therefore, 
premature infants are exposed to a much greater diversity and quantity of bacteria, viruses and 
fungi. The premature infant gut displays an excessive inflammatory response [7], and toll-like 
receptor 4 seems to play a key role in this inflammatory response ([8] see below). However, a 
difference in inflammatory response is not the only aspect of the premature infant intestine that 
might be affected. The neonatal gut also seems to be more susceptible to intestinal 
ischaemia/reperfusion injury than adult gut [9], and the activity of carbohydrate digestive 
enzymes is significantly lower in preterm intestine than term intestine, so that in a pig model the 
incidence and severity of NEC can be modulated by variation in the carbohydrate supplied [10]. 
Although gut motility appears is to be different in preterm and term infants [11], NEC does not 
seem to be related to early stooling pattern in premature infants [12]. Another potentially 
important difference between premature and term infants is that of maternal separation. Partial 
separation of mouse pups from the mother is enough to induce changes in colonic histology and 
permeability [13], although the relevance of these observations to NEC is unknown. 
Enteral feeding 
Although it has long been known that firstly, NEC predominantly occurs in premature infants 
that have been enterally fed, and secondly that human breast milk is protective towards NEC, 
we do not completely understand how the type of feed interacts with other risk factors. 
Interestingly, the protective effect of breast milk appears to be dose related [14]. A huge array 
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of protective factors present in breast milk has been suggested (summarized [15]) and some of 
these have been suggested as potential preventative measures or treatments (see below). One 
mechanism by which feed components could influence intestinal gene expression is epigenetics, 
with epigenetic changes defined as ‘relating to or arising from non-genetic influences on gene 
expression’. As epigenetic changes frequently involve methylation, they are potentially 
influenced by diet. A current area of research interest is the potential epigenetic effects of 
breast milk and other enteral feeds [16]. Marked epigenetic changes have been observed in the 
intestine of premature infants [17], and in a pig model, enteral feeding has been linked with 
epigenetic changes causing upregulation of pro-inflammatory genes [18]. In addition, the type of 
enteral feed can also interact with other risk factors described below such as the gut 
microbiome [19] and intestinal blood flow [20]. 
Intestinal microbiome 
While the precise role of bacterial agents in the development of NEC is unclear, several factors 
implicate their involvement. Occasionally NEC is observed to occur in clusters, in which a higher 
than expected number of cases are observed in one centre [21]. Identical organisms are grown 
from babies within these clusters and the initiation of infection control measures has been 
shown to control such outbreaks [22]. However, different organisms are grown from separate 
outbreaks so it cannot be claimed that a single organism is involved in development of NEC. 
Bacterial involvement in the pathogenesis of NEC is also implicated by association; 
endotoxaemia [23, 24] and positive blood cultures are common in infants with NEC and the 
gastrointestinal pneumatosis found in NEC contains 30% hydrogen [25], a gas produced solely by 
bacterial metabolism. As long ago as 1975, it was hypothesized that a dysbiosis (imbalance 
between protective microflora and harmful microflora) was involved in the pathogenesis of NEC 
[26]. The recent explosion of interest in the intestinal microbiome, and the availability of high 
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throughput pyrosequencing techniques, has led to several relevant research studies in NEC. 
However, such data are very complex, and analysis of these data in a very heterogeneous 
disease like NEC is extremely challenging, especially where both the nosocomial microbiota and 
their measurement methods vary between neonatal units [27].  Nevertheless, recent studies 
suggested a loss in microbial diversity to occur immediately before NEC onset [28, 29], with a 
consequent predominance of Escherichia spp. [28] or strict anaerobes [29].  
Inflammation 
Histologically, there is a massive intestinal inflammatory response in NEC. Some authors have 
even suggested that there may be antenatal precedents to this exaggerated inflammatory 
response, such as chorioamnionitis. A recent systematic review and meta-analysis of available 
studies concluded that chorioamnionitis with fetal involvement, and clinical chorioamnionitis 
both significantly increased the risk of NEC, whereas there was no increased risk from 
histological chorioamnionitis [30]. Differences in the immune response to mucosal damage and 
the microbiota may also be responsible for the exaggerated inflammatory response in NEC 
(reviewed [31]). Recent studies have highlighted such differences, such as those showing that 
intraepithelial T cell receptor γδ lymphocytes are decreased in surgical NEC specimens 
compared with appropriate controls [32] as are lamina propria T regulatory cells [33]. A key 
player in intestinal inflammation and the response to pathogens is TLR4, and recent work has 
shown that TLR4 signalling is important in the development of NEC [8, 34-36]. Intriguingly, TLR4 
signalling also links to other factors involved in the pathogenesis of NEC, such as the 
microcirculation ([36] see below). 
Ischaemic injury 
 From early descriptions, ischaemia/reperfusion injury due to relative splanchnic 
hypoperfusion (the so called ‘diving reflex’) was though to play a part in the pathogenesis of NEC 
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[26], in part due to the similarity in histological damage between intestinal ischaemic damage 
(such as that following mesenteric infarction) and NEC. A primary role for intestinal ischaemic 
damage long fell out of favour (for discussion, see [37]), but recently some evidence from both 
animal models and clinical studies has resurrected the potential role of intestinal ischaemia, 
although probably not as the sole initiating factor. Experimental studies have suggested that in 
NEC, there is an impairment in intestinal microcirculation [37-39] which can be improved by 
direct peritoneal resuscitation [40-43].  A potential role for splanchnic hypoperfusion in NEC has 
been suggested from a variety of clinical studies: firstly, there is a decline in mesenteric 
oxygenation when preterm infants are fed during red blood cell transfusion [44] (which may 
itself be associated with precipitation of acute NEC [45]). Secondly, there is increasing 
recognition that an important subset of infants with NEC have congenital cardiac disease that 
may predispose to splanchnic hypoperfusion [46]. Thirdly, several clinical studies have suggested 
that arginine and/or citrulline, amino acids which are important in production of nitric oxide and 
regulation of intestinal blood flow, are decreased in NEC and that supplementation of infants 
with arginine may prevent NEC [47-51]. Interestingly, the importance of the arginine/citrulline 
axis in pathogenesis of NEC is also emphasized by other studies which show that regulation of 
the genes of arginine biosynthesis is altered in human NEC [52, 53], that amount of proteins of 
the arginine biosynthetic pathway is altered in experimental NEC [54], that polymorphisms in 
the enzyme carbamoyl phosphate synthase, a key gene in arginine biosynthesis, are associated 
with NEC development [55] and that experimental enterocyte-specific knockdown of the 
enzyme argininosuccinate lyase results in an increased incidence of NEC [56]. However, it should 
also be noted the function of arginine is not solely related to regulation of blood flow, but that it 
is also an important amino acid in immune function and wound healing, two other processes 
that are potentially impaired in NEC. 
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Diagnosis 
Diagnosis of NEC currently relies on a combination of clinical symptoms and signs, and 
radiological features such as pneumatosis intestinalis and pneumoperitoneum, which are 
encapsulated in the Bell’s stages of disease, which although frequently criticized, are still widely 
used to describe populations of infants with NEC. For many years, researchers have sought 
biomarkers that would be diagnostic for NEC in plasma, urine or stool samples (reviewed [57, 
58]). One of the most widely researched proposed biomarkers is intestinal fatty acid binding 
protein (I-FABP), which is released into the circulation from damaged enterocytes, and is 
excreted in urine. It has been shown in many studies that I-FABP is increased around the time of 
development of NEC [59, 60]. However, I-FABP concentrations in healthy premature infants are 
somewhat variable and the half-life of I-FABP in plasma is short, so that use of I-FABP 
concentration in plasma or urine to diagnose early NEC is limited. Similarly, although I-FABP can 
usefully distinguish those infants that have more extensive disease and thus require more 
extensive resection [59, 61], the short half-life means that unless there is ongoing enterocyte 
damage, some infants with very extensive disease can have paradoxically low I-FABP levels 
(presumably as all the enterocytes have been lost) [59]. Recently, biomarker discovery studies of 
the urinary proteome [62] and peptidome [63] have identified proteins and peptides associated 
with poor outcome (i.e. disease progression). Importantly, the biomarkers alone were not able 
to completely distinguish progressors from non-progressors, but were able to when clinical 
factors were incorporated into the prediction model too. This raises the question of the clinical 
utility of these markers – neither an ELISA (for I-FABP) nor mass-spectrometry are currently 
anywhere near point-of-care testing, so whether they can be usefully incorporated into medical 
and surgical decision making, particularly when clinical information also has to be taken into 
account, is uncertain. 
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Another type of biomarker that has also seen recent interest is the use of analysis of volatile 
organic compounds (VOCs) in stool samples as markers of bacterial metabolism. In one pilot 
study, it was shown that a difference in VOC profile in stool samples between control infants 
and infants with NEC could be used to predict NEC before clinical symptoms [64], and a larger 
study aimed to corroborate these findings is currently underway. Another recent study used an 
‘electronic nose’ system, in which VOCs are not quantitatively measured, but differences in 
intensity across an array of sensors are used to discriminate samples. The study showed that 
fecal VOC profiles of infants with NEC could be discriminated from controls, from 2-3 days 
predating the onset of clinical symptoms [65]. Again, there may be problems in utilizing these 
interesting biomarkers in a clinically useful way, 
 Given that most very low birthweight or extremely low birthweight infants will have 
some form of continual monitoring of heart rate, pulse oximetry and other physiological 
parameters, it would be useful to incorporate these measures into early warning tools to predict 
NEC. Some neonatal units are now incorporating sophisticated analysis algorithms into their 
bedside monitoring, and ultimately these may provide just such a prediction tool. Abnormal 
heart rate characteristics have been suggested as a useful clinical tool to predict clinical 
neonatal sepsis [66], and have shown initial promise to predict NEC before clinical diagnosis in a 
prospective trial setting [67]. However, a more recent study in which the same system was used 
in routine clinical practice suggested that abnormal heart rate characteristics have limited ability 
to detect sepsis [68]. 
The role of ultrasound as an imaging modality for infants with NEC has attracted 
research interest [69, 70]. Whilst plain radiology remains the primary imaging modality for 
diagnostic purposes it is clear that ultrasound has promise for imaging infants with NEC. 
Pneumatosis intestinalis and portal venous gas are both readily seen during abdominal 
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ultrasound and in fact PVG may be detected earlier by US than by plain radiography  [71].  
However it is the ability of ultrasound to detect infants with more advanced disease and those 
who may benefit from surgery that has attracted greatest attention. Ultrasound permits 
examination of the intestinal wall in a much more detailed way than is possible with plain 
radiographs and in particular allows an assessment of the thickness and perfusion of the 
intestinal wall and peristalsis [72, 73]. Characteristic perfusion patterns have been associated 
with inflammation, ischaemia and necrosis [72]. Further information that can be obtained from 
ultrasound also includes the presence of free intra-abdominal gas and the presence and nature 
of any free intra-abdominal fluid that may be indicative of intestinal perforation. The real 
challenge is to determine whether US can be used to accurately identify infants with NEC who 
would benefit from surgery [72][74]). Further prospective evaluation is undoubtedly needed. 
Near infra-red spectroscopy (NIRS) has also been investigated by researchers who believe it may 
be useful at predicting risk of NEC [75][76], distinguishing infants with NEC from those without 
and for the identification of infants with advanced NEC. NIRS measures oxygenation at the tissue 
level using probes placed on the skin and is limited by a short depth of tissue penetration, 
typically (<1cm). NIRS probes placed on the abdominal wall may therefore give an indication of 
the state oxygenation of some of the underlying intestine. NIRS does not have the ability 
however to determine oxygenation in the entire intestine. Despite this, differences have been 
detected in splanchnic tissue oxygenation values using NIRS between preterm infants who 
subsequently developed NEC and those who did not [75, 76][77]. Whether NIRS can be used 
with clinical benefit to prevent NEC with infants with NEC remains to be seen.  
 
Prevention 
Dietary / pharmacological approaches 
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There are several suggested dietary and/or pharmacological approaches to the prevention of 
NEC. Many of these agents are found in human breast milk, for example lactoferrin is a 
glycoprotein that forms part of the innate immune response. It is found in high concentration in 
colostrum and lower concentration in breast milk and has antibacterial and antiviral properties. 
It has been speculated that it would be a potential preventative measure for NEC, but few 
animal or human studies have yet been carried out to establish its efficacy. A small randomised 
study in VLBW infants found that episodes of sepsis were reduced in infants given oral human 
lactoferrin (4.4 vs. 17.3/1,000 patient days, p = 0.007) but none in the treatment or placebo 
group developed NEC [78]. A randomised controlled trial of bovine lactoferrin showed a reduced 
incidence of NEC compared to controls, and a reduced risk of death or progression to stage 3 
NEC [79]. Oligosaccharides are complex carbohydrates that are components present at much 
higher concentration in human breast milk than formula. They have been shown to prevent NEC 
in a rodent model [80], have shown promise in preventing NEC in a limited human trial [81] and 
seem to have generated a recent flurry of activity amongst patent lawyers. Another series of 
compounds that have potential use in preventing NEC is a new class of TLR4 inhibitors, which by 
preventing TLR4 activation may inhibit the inflammatory cascade in NEC [82, 83]. 
Probiotics 
A huge amount of interest and hope bordering on evangelism has been invested in the routine 
administration of probiotics to prevent or eradicate this disease. Neonatologists are quite 
polarized on the issue of probiotics to prevent NEC: proponents of probiotics regard the fact 
that probiotics are not routinely given to premature neonates as unethical, detractors regard 
the meta-analyses combining different probiotic strains as deeply scientifically flawed. The 
American Pediatric Surgical Association Outcomes and Clinical Trials Committee considered the 
level of evidence for routine probiotic supplementation and concluded that ‘Substantial data 
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support routine supplementation of enteral intake with probiotics in premature infants to reduce 
the incidence of severe NEC (Grade A/B). No formal recommendations regarding the 
formulation, timing or duration of supplementation could be determined, but at least one 
probiotic formulation initiated in the first week of life and continued for at least two weeks 
appears appropriate.’ [84]. However, it was also noted in this review that ‘No conclusions 
regarding probiotic use in ELBW (< 1000 grams) infants could be extrapolated from the studies 
due to limited data.’. As this population of preterm infants is exactly that at the most risk from 
NEC, we need further evidence of efficacy and safety in this group, and eagerly await the results 
of the UK based PIPs trial, which recruited 1315 infants <31 weeks completed gestation [85]. 
One aspect that contributes to unease regarding clinical uptake of probiotics, but might 
ultimately help to define a product, is the lack of mechanistic understanding of how probiotics 
might prevent NEC. The literature on potential mechanisms of probiotic action is mainly from 
experimental models. Although there are various experimental models of NEC, and several have 
been used to examine the effects of probiotics in NEC, none seem to completely recapitulate 
the human condition [86]. Data from a clinically relevant model (spontaneous NEC in premature 
pigs) hint as to why routine introduction of probiotics is less than straightforward. In 2 separate 
studies, by the same group, divergent results were obtained [87, 88]. In one study, probiotics 
decreased severity of NEC lesions (but did not affect incidence) [87], whereas in the other, 
probiotics significantly increased the incidence and severity of NEC [88]. These differing results 
illustrate in a microcosm the multifactorial and unpredictable nature of NEC and why we might 
not always expect consistent effects from probiotic administration to premature infants with 
very different microbiota. 
A general assumption is that probiotics may reduce the incidence of NEC by altering the gut 
microbiome in favour of a more ‘friendly’ population of bacterial species which in turn reduces 
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the risk of NEC. However, alteration of gut flora is only one potential mechanism by which 
probiotics might prevent NEC. Other mechanisms include effects on the gut immune system and 
via TLR-related signaling [89, 90] and effects on mucosal integrity and intestinal permeability 
[91, 92]. However, whether these are primary or secondary effects is extremely difficult to 
dissect, as the microbiome, immune system, mucosal integrity and gut barrier function are all 
mutually interdependent. Mechanistic studies in human infants are clearly difficult, but the 
group of Walker and Nanthakumar [93] has established protocols using immature human 
intestine that provides mechanistic insights. In one of these, intestinal tissue from therapeutic 
terminations of pregnancy is implanted in immune-deficient mice, the xenografts allowed to 
mature for 20 or 30 weeks to model immature intestine (i.e. susceptible to NEC) or mature 
intestine respectively, and then challenged with inflammatory stimuli. In addition, enterocytes 
were isolated from resected ileum of an infant with NEC. Using these model systems, probiotic 
bacteria decreased inflammation, but, intriguingly, these effects could be reproduced by a small 
soluble factor produced by the probiotic bacteria. These data are supported by further studies 
which suggest that soluble factors secreted by Bifidobacterium infantis and Lactobacillus 
acidophilus are effective in preventing enterocyte damage [94, 95].  If this soluble factor(s) were 
to be identified, it might be possible to use this factor pharmacologically for NEC prophylaxis, 
which may be easier to get accepted into routine clinical practice than a pot pourri of probiotics. 
Intriguingly, it has recently been suggested that the bacterial DNA alone of the probiotic strain 
Lactobacillus rhamnosus HN001 is sufficient to protect against NEC in a mouse model via 
activation of the TLR9 pathway [96]. A greater mechanistic understanding of the actions of 
probiotics may also allow development of surrogate endpoints of effectiveness, and refinement 
of probiotic regimes, as well as development of pharmacological agents. 
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Therapy 
Antibiotics are the mainstay of conservative treatment of NEC. The type of agent used varies 
between neonatal units, with little evidence to support one regime over another. A Cochrane 
review in 2014 found only two small trials, dating from the 1980s which compared different 
regimes including ampicillin, gentamicin and clindamycin [97]. An association between 
clindamycin and increased risk of post-NEC stricture was found and clindamycin is not 
recommended. Recently a cohort study found that adding metronidazole to broad spectrum 
antibiotics did not prevent deterioration of established NEC [98]. A large Canadian case control 
study of anaerobic antimicrobials found decreased mortality in surgical patients, but an 
increased risk of strictures in infants who had anaerobic antibiotics including Clindamycin, 
Metronidazole, Piperacillin-Tazobactam and Carbapenems. They observed a decrease in the use 
of Clindamycin and an increasing use of Metronidazole over a 15 year period [99]. They 
recommend a trial to assess the safety of different antibiotic regimes in neonatal care (SCAMP 
NCT01994993)[100].  
Debates on the risks of enteral feeding in causing or worsening NEC continue, but a study 
recently tried to establish whether parenteral nutrition was protective – limited by its nature as 
a retrospective cohort study, it found that infants on PN were more likely to have NEC earlier in 
life, but had no increase in the need for surgery or mortality [101]. It would be interesting to 
study this effect in a randomised controlled trial. 
Research into medical treatments for NEC have focused on agents that modulate the immune 
response, as an immature immune response is thought to be a factor in the pathogenesis of NEC 
[102].  A Cochrane review found that there was very weak evidence for the use of pentoxifylline, 
a phosphodiesterase inhibitor, as an adjunct to antibiotics in the treatment of sepsis in 
neonates, with a relative risk of NEC of 0.62 [0.26, 1.43][103, 104] In a rat model, intra-
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peritoneal pentoxifylline reduced the incidence and severity of NEC [105], but trials comparing 
the use of IV pentoxifylline in premature neonates have not yet been completed.[106] 
Another potential medical treatment is intestinal alkaline phosphatase (IAP), a protein found in 
the intestinal brush border and secreted in the bowel lumen. Previous studies have shown that 
exogenous IAP may prevent intestinal damage, but unfortunately a recent study using a rat 
model of NEC did not find that it was an effective treatment once NEC was initiated [107]. 
Recent evidence from three different research groups has suggested that stem cells are able to 
influence the course of the disease in experimental NEC (reviewed [108]): amniotic fluid stem 
cells [109], mesenchymal stem cells [110, 111] and enteric neural stem system cells [112]. In 
addition to the beneficial effects of AFS cells and the conditioned medium from AFS cells, other 
recent evidence highlights the potential role of factors in amniotic fluid in the prevention and/or 
treatment of NEC. Pig and human amniotic fluid, centrifuged so presumed to be largely cell-free, 
have been shown to stimulate proliferation and migration of rat intestinal epithelial cells in vitro 
[113]. In a well-established, clinically relevant model of spontaneous NEC in preterm piglets, 
postnatal minimal enteral feeding with porcine amniotic fluid decreased inflammation together 
with incidence and severity of NEC[114], but had no effect when given later, with full enteral 
feeding, although the beneficial effect during minimal enteral feeding was not consistently 
observed [113] [114]. Another group has shown that enteral delivery of amniotic fluid decreases 
severity of NEC in a mouse model [115]. This effect was shown to be mediated via epidermal 
growth factor (EGF) present in amniotic fluid, and its receptor, epidermal growth factor rector 
(EGFR). In additional experiments, both in vitro and in vivo it was shown that amniotic fluid 
modulates the ability of lipopolysaccharide to trigger toll-like 4- receptor (TLR4) –dependent 
inflammatory signalling, and these effects were mediated via EGF/EGFR[115]. It has also been 
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suggested that these protective effects of amniotic fluid are mediated via hepatocyte growth 
factor [116]. 
 
Conclusions 
Despite understanding the cardinal features involved in the pathogenesis of NEC, and decades 
of research, we still do not fully understand this devastating disease, how to prevent it or treat 
it. Nevertheless, the broad range and depth of research on the topic does lead to a degree of 
optimism that clinicians and scientists will hopefully be able to deliver novel preventative, 
diagnostic and therapeutic strategies that will translate into improved outcomes. 
Research Directions 
 
 Testing of research-based biomarkers in large clinical cohorts to determine whether they 
improve decision-making 
 Improve understanding of the interplay between microbiota and intestinal inflammation 
 Elucidation of the molecular basis of the protective effect of probiotics, in order to optimise 
probiotic strains to be used in prevention of NEC 
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